New study tracks daily life changes in MS patients on ofatumumab

NCT ID NCT06157086

Ongoing Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated May 15, 2026 · Updated 20 times

Summary

This study follows 302 adults with multiple sclerosis in France who are starting ofatumumab as part of their normal care. Researchers will use questionnaires to measure how the treatment affects quality of life over 12 months. The goal is to understand real-world benefits, not to test a new drug.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Novartis Investigative Site

Angers, France, 49933, France
Novartis Investigative Site

Paris, France, F-75571, France
Novartis Investigative Site

Agen, 47923, France
Novartis Investigative Site

Altkirch, 68130, France
Novartis Investigative Site

Amiens, 80054, France
Novartis Investigative Site

Belfort, 90000, France
Novartis Investigative Site

Bordeaux, 33076, France
Novartis Investigative Site

Boulogne-sur-Mer, 62200, France
Novartis Investigative Site

Brest, 29200, France
Novartis Investigative Site

Brunstatt Didenheim, 68350, France
Novartis Investigative Site

Cahors, 46000, France
Novartis Investigative Site

Chambéry, 73000, France
Novartis Investigative Site

Cherbourg Octeville, 50102, France
Novartis Investigative Site

Compiègne, 60200, France
Novartis Investigative Site

Contamine-sur-Arve, 74130, France
Novartis Investigative Site

Dax, 40107, France
Novartis Investigative Site

Gonesse, 95503, France
Novartis Investigative Site

Le Bouscat, 33110, France
Novartis Investigative Site

Le Coudray, 28630, France
Novartis Investigative Site

Lens, 62307, France
Novartis Investigative Site

Libourne, 33505, France
Novartis Investigative Site

Lille, 59000, France
Novartis Investigative Site

Lille, 59037, France
Novartis Investigative Site

Lyon, 69008, France
Novartis Investigative Site

Lyon, 69275, France
Novartis Investigative Site

Mantes-la-Jolie, 78200, France
Novartis Investigative Site

Marseille 01, 13001, France
Novartis Investigative Site

Meaux, 77104, France
Novartis Investigative Site

Metz-Tessy, 74374, France
Novartis Investigative Site

Mont-de-Marsan, 40024, France
Novartis Investigative Site

Montluçon, 03100, France
Novartis Investigative Site

Montpellier, 34090, France
Novartis Investigative Site

Mulhouse, 68100, France
Novartis Investigative Site

Nîmes, 30029, France
Novartis Investigative Site

Orsay, 91400, France
Novartis Investigative Site

Paris, 75014, France
Novartis Investigative Site

Paris, 75017, France
Novartis Investigative Site

Poissy, 78303, France
Novartis Investigative Site

Quint-Fonsegrives, 31130, France
Novartis Investigative Site

Reims, 51092, France
Novartis Investigative Site

Rennes, 35033, France
Novartis Investigative Site

Saverne, 67700, France
Novartis Investigative Site

Sélestat, 67600, France
Novartis Investigative Site

Strasbourg, 67000, France
Novartis Investigative Site

Toulouse, 31059, France
Novartis Investigative Site

Tours, 37044, France
Novartis Investigative Site

Valence, 26953, France
Novartis Investigative Site

Vannes, 56017, France
Novartis Investigative Site

Villeurbanne, 69100, France

Conditions

Explore the condition pages connected to this study.

MULTIPLE SCLEROSIS (MS)